Cited by 137Antifungal resistance and susceptibilityFungal Infections and StudiesNosocomial Infections in ICU

Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006–2008)

Open access
Klingspor, L., Tortorano, A.M., Peman, J., Willinger, B., Hamal, P., Sendid, B., Velegraki, A., Kibbler, C. +6 more·2015·Clinical Microbiology and Infection

Abstract

A prospective, observational, multicentre study of invasive candidosis (IC) in surgical patients in intensive care units (ICUs) was conducted from 2006 to 2008 in 72 ICUs in 14 European countries. A total of 779 patients (62.5% males, median age 63 years) with IC were included. The median rate of candidaemia was 9 per 1000 admissions. In 10.8% the infection was already present at the time of admission to ICU. Candida albicans accounted for 54% of the isolates, followed by Candida parapsilosis 18.5%, Candida glabrata 13.8%, Candida tropicalis 6%, Candida krusei 2.5%, and other species 5.3%. Infections due to C. krusei (57.9%) and C. glabrata (43.6%) had the highest crude mortality rate. The most common preceding surgery was abdominal (51.5%), followed by thoracic (20%) and neurosurgery (8.2%). Candida glabrata was more often isolated after abdominal surgery in patients ≥60 years, and C. parapsilosis was more often isolated in neurosurgery and multiple trauma patients as well as children ≤1 year of age. The most common first-line treatment was fluconazole (60%), followed by caspofungin (18.7%), liposomal amphotericin B (13%), voriconazole (4.8%) and other drugs (3.5%). Mortality in surgical patients with IC in ICU was 38.8%. Multivariate analysis showed that factors independently associated with mortality were: patient age ≥60 years (hazard ratio (HR) 1.9, p 0.001), central venous catheter (HR 1.8, p 0.05), corticosteroids (HR 1.5, p 0.03), not receiving systemic antifungal treatment for IC (HR 2.8, p <0.0001), and not removing intravascular lines (HR 1.6, p 0.02).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmi.2014.08.011

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the European Confederation of Medical Mycology Candida studies, the proportion of C. albicans causing candidemia decreased from 56.4% in 1997-1999, to 54% in 2006-2008, to 46.2% in 2018, with corresponding increases in non-albicans species.

    “While that decreasing trend is ubiquitous, with the series of multicenter European Confederation of Medical Mycology (ECMM) Candida studies showing the proportion of C. albicans causing candidemia decreased from 56.4% in 1997–1999,57 to 54% in 2006–2008,58 to 46.2% in 201856 with corresponding increases in non-albicans species (Table 1), there are important geographic differences.”

    From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [58]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Summarizing all of Europe, the increase in the proportion of C. glabrata between 2006-2008 (13.8%) and 2018 (21.4%) has been striking.

    “Summarizing all of Europe together, the increase in the proportion of C. glabrata between 2006–2008 (13.8%)58 to 2018 (21.4%)56 has been striking.”

    From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [58]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 35 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [18]18. Malani AN, Psarros G, Malani PN, Kauffman CA. Is age a factor for Candida Glabrata colonization. Mycoses 2012;54:531-7.

Cited by

Sorted by citations

Authors
Klingspor, L., Tortorano, A. M., Peman, J., Willinger, B., Hamal, P., Sendid, B., Velegraki, A., Kibbler, C., Meis, J. F., Sabino, R., Ruhnke, M., Arikan-Akdagli, S., Salonen, J., & Dóczi, I.
Affiliations
  • Karolinska University Hospital (SE)
  • University of Milan (IT)
  • Medical University of Vienna (AT)
  • Palacký University Olomouc (CZ)
  • Inserm (FR)
  • National and Kapodistrian University of Athens (GR)
  • The Royal Free Hospital (GB)
  • Radboud University Medical Center (NL)
  • National Institute of Health Dr. Ricardo Jorge (PT)
  • Charité – Universitätsmedizin Berlin (DE)
  • Päijät-Hämeen Keskussairaala (FI)
  • University of Szeged (HU)
Corresponding author
Klingspor, L.
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2015-01
Volume
21
Issue
1
Pages
87.e1-87.e10
ISSN
1198-743X (ISSN-L)
OpenAlex
W2092769417
Cited by
137
References
35
Citations by year
2026: 3 · 2025: 13 · 2024: 15 · 2023: 13 · 2022: 8 · 2021: 6 · 2020: 15 · 2019: 14 · 2018: 16 · 2017: 17 · 2016: 13 · 2015: 4
FWCI
7.94
Type
journal article
Language
en
Open access
Locations
  • Clinical Microbiology and Infection (publishedVersion)
  • PubMed (publishedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion)
Funders
Merck Sharp and Dohme
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
Keywords
invasive candidiasis, candidemia, intensive care unit, surgical patients, Candida albicans, Candida parapsilosis, Candida glabrata, Candida krusei, Candida tropicalis, mortality risk factors, antifungal therapy, central venous catheters, corticosteroids, abdominal surgery, neurosurgery, polytrauma, fluconazole, caspofungin, liposomal amphotericin B, voriconazole
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Intensive Care Units, Male, Middle Aged, Prospective Studies, Surgical Procedures, Operative, Antibiotic Prophylaxis, Young Adult, Candidiasis, Invasive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review